Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633074 | 0.85 | AR (0.67) | ARSMN1; SMN2TSHRMEN1LMNA | |
| SCHEMBL634133 | 0.83 | AR (0.65) | ARSMN1; SMN2TSHRMEN1LMNA | |
| SCHEMBL11474265 | 0.82 | AR (0.64) | ARSMN1; SMN2TSHRMEN1LMNA | |
| Nilutamide SCHEMBL29351021 | 0.82 | AR (1.00) | ARSMN1; SMN2TSHRMEN1LMNA | |
| Nilutamide SCHEMBL1462011 | 0.82 | AR (1.00) | ARSMN1; SMN2TSHRMEN1LMNA | |
| Nilutamide SCHEMBL12670 | 0.82 | AR (1.00) | ARSMN1; SMN2TSHRMEN1LMNA | |
| Nilutamide SCHEMBL28562851 | 0.81 | AR (0.98) | ARSMN1; SMN2TSHRMEN1LMNA | |
| SCHEMBL11463857 | 0.79 | AR (0.59) | ARSMN1; SMN2TSHRMEN1LMNA | |
| Nilutamide SCHEMBL20695037 | 0.77 | AR (0.89) | ARSMN1; SMN2TSHRMEN1LMNA | |
| Nilutamide SCHEMBL5579273 | 0.77 | AR (0.89) | ARSMN1; SMN2TSHRMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102428073-B | Imidazolidine-2,4-dione derivative and the purposes as cancer drug thereof | IPSEN PHARMA S.A.S. (FR) | 2015-09-30 | — | — | CN | claimed |
| US-8710091-B2 | Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug | IPSEN PHARMA S.A.S. (FR) | 2014-04-29 | — | — | US | claimed |
| EP-2419410-B1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA SAS (FR) | 2013-03-06 | — | — | EP | claimed |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-04-05 | — | — | US | claimed |
| EP-2419410-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2012-02-22 | — | — | EP | claimed |
| WO-2010119193-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | claimed |
| US-9650382-B2 | Heteroarylamide derivatives having antiandrogenic properties | ARANDA PHARMA LTD (FI) | 2017-05-16 | — | — | US | disclosed |
| US-9296716-B2 | Androgen receptor ligands | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIV. TRINITY OF QUEEN ELIZABETH NEAR DUBLIN (IE) | 2016-03-29 | — | — | US | disclosed |
| CN-102428073-B | Imidazolidine-2,4-dione derivative and the purposes as cancer drug thereof | IPSEN PHARMA S.A.S. (FR) | 2015-09-30 | — | — | CN | disclosed |
| US-20150168424-A1 | IGFBP2 Biomarker | WANG YAN (US) | 2015-06-18 | — | — | US | disclosed |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | MERCK SHARP & DOHME (US) | 2015-04-02 | — | — | US | disclosed |
| US-20150005308-A1 | NOVEL HETEROARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | ARANDA PHARMA LTD (FI) | 2015-01-01 | — | — | US | disclosed |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy (IE) | 2014-12-04 | — | — | US | disclosed |
| US-20110262525-A1 | METHODS OF TREATMENT | SCHERING CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | XOMA TECHNOLOGY LTD. | 2011-04-28 | — | — | US | disclosed |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | MERCK SHARP & DOHME CORP. | 2011-04-21 | — | — | US | disclosed |
| US-20110014117-A1 | ANTI-IGF1R | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | SCHERING CORPORATION | 2011-01-13 | — | — | US | disclosed |
| WO-2010119193-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010119194-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110097340-A1 | FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING | VEGFA, KDR, FLT4 | AR 3248/4885SMN1; SMN2 4415/4885TSHR 669/4885 |
| US-20150168424-A1 | IGFBP2 Biomarker | IGFBP2, IGFBP1, IGFBP5 | AR 737/4885SMN1; SMN2 1192/4885TSHR 69/4885 |
| US-20110014117-A1 | ANTI-IGF1R | IGF1R, IGFBP1, IGFBP2 | AR 756/4885SMN1; SMN2 2621/4885TSHR 64/4885 |
| US-20150005308-A1 | NOVEL HETEROARYLAMIDE DERIVATIVES HAVING ANTIANDROGENIC PROPERTIES | AR, NR5A1, CYP19A1 | AR 1/4885SMN1; SMN2 4762/4885TSHR 235/4885 |
| US-20120083514-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES, AND USE THEREOF AS A CANCER DRUG | MKI67, CCND2, CCND1 | AR 1752/4885SMN1; SMN2 1773/4885TSHR 1447/4885 |
| US-20110009387-A1 | HISTONE H2AX (HH2AX) BIOMARKER FOR FTI SENSITIVITY | TERF2IP, TERF2, DOT1L | AR 4144/4885SMN1; SMN2 3879/4885TSHR 2491/4885 |
| US-20110262525-A1 | METHODS OF TREATMENT | ASAH2, FOLH1, CD44 | AR 2173/4885SMN1; SMN2 818/4885TSHR 3076/4885 |
| US-20110091524-A1 | BIOMARKERS FOR SENSITIVITY TO ANTI-IGF1R THERAPY | IGF1R, IGFBP1, IGFBP2 | AR 475/4885SMN1; SMN2 2063/4885TSHR 148/4885 |
| US-20150093398-A1 | Methods and Compositions for Treating or Preventing Cancer | BRCA1, VHL, TP53 | AR 1666/4885SMN1; SMN2 1239/4885TSHR 4841/4885 |
| US-20140357682-A1 | ANDROGEN RECEPTOR LIGANDS | AR, NR5A1, SHBG | AR 1/4885SMN1; SMN2 3751/4885TSHR 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.